• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TOPCAT(醛固酮拮抗剂治疗射血分数保留的心力衰竭)试验中的舒张期血压与不良结局。

Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.

机构信息

Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.

Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA

出版信息

J Am Heart Assoc. 2018 Feb 23;7(5):e007475. doi: 10.1161/JAHA.117.007475.

DOI:10.1161/JAHA.117.007475
PMID:29475874
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5866321/
Abstract

BACKGROUND

Although diastolic blood pressure (DBP) is independently associated with an increased risk of adverse cardiovascular outcomes in the general population, it is unclear if a similar relationship exists in patients with heart failure with preserved ejection fraction.

METHODS AND RESULTS

This analysis included 1703 (mean age, 72±10 years; 50% men; 78% white) patients with heart failure with preserved ejection fraction enrolled in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial from the Americas who were treated for hypertension. Multivariable Cox regression was used to examine the risk of hospitalization for heart failure, death, and cardiovascular death associated with DBP. The relationship between hospitalization for heart failure and DBP was linear, with an increased risk observed with decreasing DBP values (≥90 mm Hg: referent; 80-89 mm Hg: hazard ratio [HR], 1.44; 95% confidence interval [CI], 0.85-2.44; 70-79 mm Hg: HR, 1.18; 95% CI, 0.69-2.01; 60-69 mm Hg: HR, 1.54; 95% CI, 0.90-2.63; <60 mm Hg: HR, 2.12; 95% CI, 1.20-3.74; =0.0055 for trend). The associations of DBP with death (≥90 mm Hg: HR, 1.86; 95% CI, 1.12-3.06; 80-89 mm Hg: HR, 1.23; 95% CI, 0.89-1.70; 70-79 mm Hg: referent; 60-69 mm Hg: HR, 1.20; 95% CI, 0.90-1.59; <60 mm Hg: HR, 1.68; 95% CI, 1.21-2.33) and cardiovascular death (≥90 mm Hg: HR, 2.02; 95% CI, 1.10-3.71; 80-89 mm Hg: HR, 1.17; 95% CI, 0.77-1.79; 70-79 mm Hg: referent; 60-69 mm Hg: HR, 1.16; 95% CI, 0.80-1.70; <60 mm Hg: HR, 1.85; 95% CI, 1.21-2.82) were nonlinear, with a greater risk of each outcome observed with DBP values ≥90 and <60 mm Hg.

CONCLUSIONS

DBP values ≥90 and <60 mm Hg are associated with a significant risk of adverse outcomes in patients with heart failure with preserved ejection fraction who are treated for hypertension. Further research is needed to determine optimal DBP targets to reduce the risk of adverse events in patients with heart failure with preserved ejection fraction.

摘要

背景

尽管舒张压(DBP)与一般人群中不良心血管结局的风险增加独立相关,但在射血分数保留的心力衰竭患者中是否存在类似的关系尚不清楚。

方法和结果

本分析纳入了 1703 名(平均年龄 72±10 岁;50%为男性;78%为白人)接受降压治疗的射血分数保留的心力衰竭患者,他们来自美洲的 TOPCAT(醛固酮拮抗剂治疗保留心脏功能的心力衰竭)试验。多变量 Cox 回归用于检查与 DBP 相关的心力衰竭住院、死亡和心血管死亡的风险。与 DBP 相关的心力衰竭住院呈线性关系,随着 DBP 值的降低(≥90mmHg:参考值;80-89mmHg:危险比[HR],1.44;95%置信区间[CI],0.85-2.44;70-79mmHg:HR,1.18;95%CI,0.69-2.01;60-69mmHg:HR,1.54;95%CI,0.90-2.63;<60mmHg:HR,2.12;95%CI,1.20-3.74;趋势=0.0055)观察到风险增加。DBP 与死亡(≥90mmHg:HR,1.86;95%CI,1.12-3.06;80-89mmHg:HR,1.23;95%CI,0.89-1.70;70-79mmHg:参考值;60-69mmHg:HR,1.20;95%CI,0.90-1.59;<60mmHg:HR,1.68;95%CI,1.21-2.33)和心血管死亡(≥90mmHg:HR,2.02;95%CI,1.10-3.71;80-89mmHg:HR,1.17;95%CI,0.77-1.79;70-79mmHg:参考值;60-69mmHg:HR,1.16;95%CI,0.80-1.70;<60mmHg:HR,1.85;95%CI,1.21-2.82)是非线性的,观察到每个结局的风险增加与 DBP 值≥90mmHg 和<60mmHg 相关。

结论

DBP 值≥90mmHg 和<60mmHg 与接受降压治疗的射血分数保留的心力衰竭患者不良结局的显著风险相关。需要进一步研究以确定最佳的 DBP 目标,以降低射血分数保留的心力衰竭患者不良事件的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276b/5866321/6ccc8f4af9c1/JAH3-7-e007475-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276b/5866321/81a5bf6368fc/JAH3-7-e007475-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276b/5866321/c1e1f2303d12/JAH3-7-e007475-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276b/5866321/6ccc8f4af9c1/JAH3-7-e007475-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276b/5866321/81a5bf6368fc/JAH3-7-e007475-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276b/5866321/c1e1f2303d12/JAH3-7-e007475-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276b/5866321/6ccc8f4af9c1/JAH3-7-e007475-g003.jpg

相似文献

1
Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.TOPCAT(醛固酮拮抗剂治疗射血分数保留的心力衰竭)试验中的舒张期血压与不良结局。
J Am Heart Assoc. 2018 Feb 23;7(5):e007475. doi: 10.1161/JAHA.117.007475.
2
Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.螺内酯与射血分数保留的心力衰竭中的难治性高血压。
Am J Hypertens. 2018 Mar 10;31(4):407-414. doi: 10.1093/ajh/hpx210.
3
Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.螺内酯的应用与难治性高血压伴射血分数保留的心力衰竭患者结局的改善。
J Am Heart Assoc. 2020 Dec;9(23):e018827. doi: 10.1161/JAHA.120.018827. Epub 2020 Nov 23.
4
Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction.舒张压低与射血分数保留的心力衰竭不良结局相关。
Int J Cardiol. 2018 Jul 15;263:69-74. doi: 10.1016/j.ijcard.2018.04.031. Epub 2018 Apr 9.
5
Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.射血分数保留的心力衰竭患者的外周动脉疾病及不良结局风险
Clin Cardiol. 2017 Sep;40(9):692-696. doi: 10.1002/clc.22716. Epub 2017 Apr 26.
6
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.射血分数保留的心力衰竭患者的心脏结构、功能及预后:醛固酮拮抗剂治疗射血分数保留的心力衰竭(TOPCAT)试验的超声心动图研究结果
Circ Heart Fail. 2014 Sep;7(5):740-51. doi: 10.1161/CIRCHEARTFAILURE.114.001583. Epub 2014 Aug 13.
7
Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.年龄对螺内酯治疗心力衰竭疗效和安全性的影响。
JACC Heart Fail. 2019 Dec;7(12):1022-1028. doi: 10.1016/j.jchf.2019.08.019.
8
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.TOPCAT 试验中醛固酮拮抗剂治疗心脏收缩功能保留心力衰竭患者及结局的地域差异。
Circulation. 2015 Jan 6;131(1):34-42. doi: 10.1161/CIRCULATIONAHA.114.013255. Epub 2014 Nov 18.
9
Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.射血分数保留的心力衰竭患者的心率与不良结局风险
Eur J Prev Cardiol. 2017 Jul;24(11):1212-1219. doi: 10.1177/2047487317708676. Epub 2017 May 9.
10
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.心力衰竭伴射血分数保留与药物超适应证联用的相关性研究。
Circ Heart Fail. 2021 Nov;14(11):e008293. doi: 10.1161/CIRCHEARTFAILURE.120.008293. Epub 2021 Oct 22.

引用本文的文献

1
Endothelial Activation and Stress Index (EASIX) in coronary artery disease: promising biomarker or oversimplified measure?冠状动脉疾病中的内皮激活与应激指数(EASIX):是有前景的生物标志物还是过于简化的指标?
Clin Res Cardiol. 2024 Dec;113(12):1773-1774. doi: 10.1007/s00392-024-02565-5. Epub 2024 Oct 23.
2
Heart failure with preserved ejection fraction.射血分数保留的心力衰竭。
Nat Rev Dis Primers. 2024 Aug 14;10(1):55. doi: 10.1038/s41572-024-00540-y.
3
Public health impact of antihypertensive medication use on arterial blood pressure: A pooled cross-sectional analysis of population health surveys.

本文引用的文献

1
Relation of Diastolic Blood Pressure and Coronary Artery Calcium to Coronary Events and Outcomes (From the Multi-Ethnic Study of Atherosclerosis).舒张压与冠状动脉钙化与冠状动脉事件及预后的关系(来自动脉粥样硬化多民族研究)
Am J Cardiol. 2017 Nov 15;120(10):1797-1803. doi: 10.1016/j.amjcard.2017.07.094. Epub 2017 Aug 8.
2
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.2017年美国心脏病学会/美国心脏协会/美国心力衰竭学会对2013年美国心脏病学会基金会/美国心脏协会心力衰竭管理指南的重点更新:美国心脏病学会/美国心脏协会临床实践指南特别工作组及美国心力衰竭学会的报告
Circulation. 2017 Aug 8;136(6):e137-e161. doi: 10.1161/CIR.0000000000000509. Epub 2017 Apr 28.
3
降压药物使用对动脉血压的公共卫生影响:基于人群健康调查的汇总横断面分析。
PLoS One. 2023 Aug 21;18(8):e0290344. doi: 10.1371/journal.pone.0290344. eCollection 2023.
4
Expert consensus on blood pressure management in critically ill patients.危重症患者血压管理专家共识
J Intensive Med. 2023 Jul 14;3(3):185-203. doi: 10.1016/j.jointm.2023.06.001. eCollection 2023 Jul 31.
5
Presence of physical symptoms in healthy adolescence found to be associated with female gender, obesity, tachycardia, diastolic hypertension and smoking.研究发现,健康青少年出现身体症状与女性性别、肥胖、心动过速、舒张期高血压及吸烟有关。
Am J Cardiovasc Dis. 2022 Dec 15;12(6):315-319. eCollection 2022.
6
Associations of short- and long-term mortality with admission blood pressure in Chinese patients with different heart failure subtypes.不同心力衰竭亚型中国患者入院血压与短期和长期死亡率的关系。
J Clin Hypertens (Greenwich). 2022 Dec;24(12):1577-1586. doi: 10.1111/jch.14589. Epub 2022 Nov 2.
7
Effects of L-Citrulline Supplementation on Endothelial Function and Blood Pressure in Hypertensive Postmenopausal Women.补充 L-瓜氨酸对高血压绝经后女性血管内皮功能和血压的影响。
Nutrients. 2022 Oct 20;14(20):4396. doi: 10.3390/nu14204396.
8
Heart failure ejection fraction class conversions: impact of biomarkers, co-morbidities, and pharmacotherapy.心力衰竭射血分数分级转换:生物标志物、合并症和药物治疗的影响。
ESC Heart Fail. 2022 Aug;9(4):2538-2547. doi: 10.1002/ehf2.13965. Epub 2022 May 15.
9
Exercise Blood Pressure in Heart Failure With Preserved and Reduced Ejection Fraction.射血分数保留和降低的心衰患者的运动血压。
JACC Heart Fail. 2022 Apr;10(4):278-286. doi: 10.1016/j.jchf.2022.01.012. Epub 2022 Mar 9.
10
Prognostic Value of Right Ventricular Strains Using Novel Three-Dimensional Analytical Software in Patients With Cardiac Disease.使用新型三维分析软件评估右心室应变在心脏病患者中的预后价值。
Front Cardiovasc Med. 2022 Feb 25;9:837584. doi: 10.3389/fcvm.2022.837584. eCollection 2022.
Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.根据稳定型冠状动脉疾病患者的收缩压和舒张压达标情况评估心血管事件发生率和死亡率:一项国际队列研究。
Lancet. 2016 Oct 29;388(10056):2142-2152. doi: 10.1016/S0140-6736(16)31326-5. Epub 2016 Aug 30.
4
Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control.舒张压、亚临床心肌损伤与心脏事件:对血压控制的启示
J Am Coll Cardiol. 2016 Oct 18;68(16):1713-1722. doi: 10.1016/j.jacc.2016.07.754. Epub 2016 Aug 30.
5
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.射血分数保留的心力衰竭的表型特异性治疗:多器官路线图
Circulation. 2016 Jul 5;134(1):73-90. doi: 10.1161/CIRCULATIONAHA.116.021884.
6
Predicting Heart Failure With Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure Subtypes.射血分数保留和降低的心力衰竭预测:心力衰竭亚型国际协作研究
Circ Heart Fail. 2016 Jun;9(6). doi: 10.1161/CIRCHEARTFAILURE.115.003116.
7
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.强化与标准血压控制的随机试验
N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9.
8
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.TOPCAT 试验中醛固酮拮抗剂治疗心脏收缩功能保留心力衰竭患者及结局的地域差异。
Circulation. 2015 Jan 6;131(1):34-42. doi: 10.1161/CIRCULATIONAHA.114.013255. Epub 2014 Nov 18.
9
Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.射血分数保留的心力衰竭:机制、临床特征和治疗方法。
Circ Res. 2014 Jun 20;115(1):79-96. doi: 10.1161/CIRCRESAHA.115.302922.
10
Spironolactone for heart failure with preserved ejection fraction.螺内酯治疗射血分数保留的心力衰竭。
N Engl J Med. 2014 Apr 10;370(15):1383-92. doi: 10.1056/NEJMoa1313731.